These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 38991258)
1. A Quality by Design (QbD) driven gradient high performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers. Sen S; Ranjan OP J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Aug; 1243():124229. PubMed ID: 38991258 [TBL] [Abstract][Full Text] [Related]
2. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. Kralj E; Trontelj J; Pajič T; Kristl A J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection. Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095 [TBL] [Abstract][Full Text] [Related]
4. QbD-steered development and validation of an RP-HPLC method for quantification of ferulic acid: Rational application of chemometric tools. Saini S; Sharma T; Patel A; Kaur R; Tripathi SK; Katare OP; Singh B J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Oct; 1155():122300. PubMed ID: 32771967 [TBL] [Abstract][Full Text] [Related]
5. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). D'Avolio A; Simiele M; De Francia S; Ariaudo A; Baietto L; Cusato J; Fava C; Saglio G; Di Carlo F; Di Perri G J Pharm Biomed Anal; 2012 Feb; 59():109-16. PubMed ID: 22036594 [TBL] [Abstract][Full Text] [Related]
6. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. De Francia S; D'Avolio A; De Martino F; Pirro E; Baietto L; Siccardi M; Simiele M; Racca S; Saglio G; Di Carlo F; Di Perri G J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jun; 877(18-19):1721-6. PubMed ID: 19428316 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring. Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048 [TBL] [Abstract][Full Text] [Related]
8. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. Pirro E; De Francia S; De Martino F; Fava C; Ulisciani S; Cambrin GR; Racca S; Saglio G; Di Carlo F J Chromatogr Sci; 2011; 49(10):753-7. PubMed ID: 22080802 [TBL] [Abstract][Full Text] [Related]
9. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. Roche S; McMahon G; Clynes M; O'Connor R J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(31):3982-90. PubMed ID: 19854117 [TBL] [Abstract][Full Text] [Related]
10. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma. Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431 [TBL] [Abstract][Full Text] [Related]
11. Quality by design-based development and validation of an HPLC method for simultaneous estimation of pregabalin and piperine in dual drug-loaded liposomes. Gupta I; Adin SN; Aqil M; Mujeeb M; Sultana Y Biomed Chromatogr; 2023 Jan; 37(1):e5510. PubMed ID: 36100737 [TBL] [Abstract][Full Text] [Related]
12. High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma. Miura M; Takahashi N; Sawada K Biomed Chromatogr; 2010 Jul; 24(7):789-93. PubMed ID: 19904720 [TBL] [Abstract][Full Text] [Related]
13. Development of a validated liquid chromatographic method for quantification of sorafenib tosylate in the presence of stress-induced degradation products and in biological matrix employing analytical quality by design approach. Sharma T; Khurana RK; Jain A; Katare OP; Singh B Biomed Chromatogr; 2018 May; 32(5):e4169. PubMed ID: 29244215 [TBL] [Abstract][Full Text] [Related]
14. Analytical method development and validation of reverse-phase high-performance liquid chromatography (RP-HPLC) method for simultaneous quantifications of quercetin and piperine in dual-drug loaded nanostructured lipid carriers. Chaudhari VS; Borkar RM; Murty US; Banerjee S J Pharm Biomed Anal; 2020 Jul; 186():113325. PubMed ID: 32380356 [TBL] [Abstract][Full Text] [Related]
15. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
16. RP-LC Method Development and Validation for Dasatinib Forced Degradation Study: Isolation and Structural Characterization by NMR and HRMS. Kavitapu DR; Murty JNSRC; Maruthapillai A; Senadi GC; Mahapatra S J Chromatogr Sci; 2024 Apr; 62(4):347-355. PubMed ID: 37340779 [TBL] [Abstract][Full Text] [Related]
17. UPLC-MS/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions. Alzoman NZ; Maher HM; Shehata SM; Abanmy NO Biomed Chromatogr; 2019 Dec; 33(12):e4674. PubMed ID: 31376170 [TBL] [Abstract][Full Text] [Related]
18. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856 [TBL] [Abstract][Full Text] [Related]
20. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib. Elnair R; Galal A BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]